about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusNon-incretin insulin secretagogues for patients with type 2 diabetes mellitusThe management of type 2 diabetic patients with hypoglycaemic agentsMicrocirculatory effects of KATP channel blockade by sulphonylurea derivatives in humans.Are hypoglycaemia and other adverse effects similar among sulphonylureas?Thiazolidinediones: a new class of antidiabetic drugs.Achieving further glycemic control in type 2 diabetes mellitus.Improving management of type 2 diabetes mellitus: 3. Sulfonylureas.Development of a replicated database of DHCP data for evaluation of drug use.Killer proteases and little strokes--how the things that do not kill you make you stronger.Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review.Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis.Clinical review of glimepiride.Non-insulin-dependent (type II) diabetes mellitus.The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations.Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain.Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.Use of hypoglycemic drugs during lactation.Antihyperglycemic, antihyperlipidemic and antioxidative potential of Prosopis cineraria bark.Update in clinical toxicology.Use of oral antidiabetic agents during breastfeeding.Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practiceWhen diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus.Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents.Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting.Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Gliclazide does not fully prevent 2-deoxy-D-ribose-induced oxidative damage because it does not restore glutathione content in a pancreatic β-cell line.Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitusThe effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors' Pharmacare beneficiaries.Death during intensive glycemic therapy of diabetes: mechanisms and implications.The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes.The barrier of hypoglycemia in diabetes.Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan.Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Octreotide for the treatment of sulfonylurea poisoning.Sulfonylureas: a new look at old therapy.Antidiabetic Therapy in End-Stage Renal Disease.
P2860
Q24186660-12DC925D-04B6-48AA-8BB0-5C4A3403EA10Q24197884-0C3CA3BA-420B-4B81-AC6A-7487C38290A0Q24234574-707103D9-31E5-4E27-A8D3-DD86FBE2A2A5Q30417363-47180CF3-3DFF-43DC-A866-1146353A8337Q30827252-8EBD4478-93DC-4A77-9624-A06952CDC69FQ31122704-0F7FB1CB-5952-4B6C-B716-EDD35B099203Q33607634-28B31733-7FE3-49BA-9913-59D698413CF5Q33728110-0467233B-F1F8-4A86-B53E-F95C934010BAQ33806744-E8CD2639-5805-45FF-A628-9017E004F879Q33873096-463507FC-1FA2-48AA-AE51-F2C0DCB979B3Q33896931-17524C22-0E6C-43B7-B915-A13CB2543EE1Q34168385-08CD4FEE-B318-4942-9E82-5DEA505D5044Q34221721-768005CA-7C35-4D98-93CD-5AACC97F86E9Q34240998-1CEBD4E3-7B8B-4053-8152-EC969AB26F5CQ34274596-A2CD10A7-36AD-4453-B11A-ED3B99BF73E5Q34358376-E634F8A5-42E2-46EF-BE35-A9E342C2170AQ34449421-3EA2A383-9E6F-4B0A-908E-84464F82B408Q34480831-2DD6C09D-14A9-4718-BDC8-7481810600E2Q34606503-940C80F3-AC42-455F-AD43-1163459BF020Q34644676-B0BA2F35-84F6-47CA-A77D-A2F6020DA153Q34714524-82E7DCD5-5DCC-4E45-942D-BE995DF95577Q34744367-FFF3546D-05DD-4BCE-95EF-BA08D3AF6CC8Q34753635-F26F566B-E24C-4D1B-93D6-FAE186EF15D2Q34957940-A130258B-ACF7-45B6-A5A9-696DEE5F33B1Q35041412-AC94FDCD-671F-46D3-BAB5-1CCABA36059AQ35044470-69F08A83-0107-4A8E-B0F4-686FDDC5940BQ35607945-7F6357EA-CDC1-4226-9C03-27151BC25757Q35725683-FAACECF8-40B8-4E9D-B5AD-09E56D13495FQ35783714-35869BC0-F178-4581-9253-544C27452F72Q35802160-82A3E59E-8DE8-4718-A251-CB736AD0AD01Q35820260-117A27BB-4B19-47A9-9931-F8485D10BB2CQ36297059-73C31C7B-331D-4617-9A18-9FDCD0ABCD72Q36694998-75EFE615-5187-403B-8D3F-22E32498481BQ36975419-57E569AB-55DB-4982-A24F-333901B87F57Q37732688-83152DCE-A77E-4D7D-8528-1DD77BAE0A12Q37890773-D26381D9-6AB8-4CA6-8C4D-1A388F5EAA22Q38036773-F2862B3D-8D78-4CFC-BBC7-BE5D7A824CA3Q38050497-B00B879A-5ABD-4BEF-831B-875847F05D08Q38190489-BB4C01BC-6B21-45C2-8229-6719DBF16FEDQ38433245-475711B7-C0CF-462E-BA50-CF1899CCF2A6
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Oral hypoglycemic agents.
@en
type
label
Oral hypoglycemic agents.
@en
prefLabel
Oral hypoglycemic agents.
@en
P1476
Oral hypoglycemic agents.
@en
P2093
P304
P356
10.1056/NEJM198911023211805
P407
P577
1989-11-01T00:00:00Z